Mirati Therapeutics, Inc. 是一家临床阶段的靶向肿瘤学公司，今天宣布了 KRYSTAL-2 研究的第 1 期队列的阳性结果，该研究评估了 600mg BID 剂量的 adagrasib 对预先治疗的胰腺导管腺癌和其他胃肠道 (GI) 肿瘤患者的疗效携带 KRASG12C 突变，包括胆道癌、阑尾癌、小肠癌、胃食管结合部癌和食道癌。 结果表明，阿达格拉西表现出显着的临床活性和广泛的疾病控制。
从这篇文章中可以得到什么：
- , a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRASG12C mutation, including cancers of the biliary tract, appendix, small bowel, gastro-esophageal junction, and esophagus.
- .
- Results showed that adagrasib demonstrated significant clinical activity and broad disease control.
